NCT02867462

Brief Summary

The medical teams are increasingly sought by patients to get the most possible information, probably expressed in a different form and thereby supplementing the information already received. Coulter et al. reached similar conclusions in their study of the writings of patient information documents. They point out, moreover, the best adaptation of the patients better informed compared to those with less or no information. This need for information varies over time. It is present before treatment begins, continues during treatment and persists after treatment. Given the specific features of radiotherapy, the manipulators are important interlocutors to participate in the accompanying caregiver time. In conclusion, the quality of information delivered to the patient has been poorly evaluated, let alone with validated tools in this area. The impact of information on the tolerance of the treatment also needs to be confirmed, knowing that an informed patient seems less anxious and better prepared for future treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
308

participants targeted

Target at P75+ for not_applicable cancer

Timeline
Completed

Started Apr 2013

Longer than P75 for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

August 11, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 16, 2016

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 10, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 10, 2017

Completed
9.1 years until next milestone

Results Posted

Study results publicly available

June 30, 2026

Completed
Last Updated

June 30, 2026

Status Verified

June 1, 2026

Enrollment Period

4.1 years

First QC Date

August 11, 2016

Results QC Date

May 4, 2026

Last Update Submit

June 4, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • EORTC QLQ-INFO25

    Assesses the amount of information received by patients using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Information Module (EORTC QLQ-INFO25) before the first radiotherapy session. The Global Information Score will be reported. According to the EORTC scoring manual, raw scores are linearly transformed into a standardized scale ranging from a minimum of 0 to a maximum of 100. Higher values represent a better outcome (a higher level of information received), while lower values represent a worse outcome. Data will be presented as the mean value and standard deviation (SD) for each randomization arm.

    12 weeks

Study Arms (2)

A-Standard Care

OTHER

standard care

Other: Standard care

B-manipulator consultation radiotherapy added to standard care

EXPERIMENTAL

manipulator consultation radiotherapy added to standard care

Other: manipulator consultation radiotherapy added to standard care

Interventions

standard care

A-Standard Care
B-manipulator consultation radiotherapy added to standard care

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with cancer of the head and neck, esophagus, stomach, breast, rectum, anal canal, prostate, lung, bile duct, pancreas or female genital histologically proven
  • Patient being treated by radiotherapy alone or combined with chemotherapy / immunotherapy, exclusive treatment or adjuvant
  • Age over 18 years

You may not qualify if:

  • Patient has been treated with radiation to the tumor site
  • Patient with metastatic stage disease
  • Patient targeted for hypofractionated radiotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Antoine LACASSAGNE

Nice, 0, France

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Results Point of Contact

Title
Director of Clinical Trials
Organization
Centre Antoine Lacassagne

Study Officials

  • Karen BENEZERY, md

    Centre Antoine Lacassagne

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 11, 2016

First Posted

August 16, 2016

Study Start

April 1, 2013

Primary Completion

May 10, 2017

Study Completion

May 10, 2017

Last Updated

June 30, 2026

Results First Posted

June 30, 2026

Record last verified: 2026-06

Locations